---
title: "Bicycle Therapeutics: Early EphA2-Targeted Data and Multi-Tumor Expansion Potential Support Buy Rating and Upside to Valuation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283362749.md"
description: "Bicycle Therapeutics received a Buy rating from Needham analyst Ami Fadia, who set a $15.00 price target. The positive outlook is based on promising early clinical data for nuzefatide pevedotin, showing a 100% response rate in EphA2-positive metastatic urothelial carcinoma patients. Initial results in pancreatic cancer and supportive preclinical findings in head and neck squamous cell carcinoma suggest significant expansion potential. Investors are also looking forward to detailed Phase 2 results for zelenectide pevedotin, reinforcing Fadia's optimistic view on the company's valuation and growth prospects."
datetime: "2026-04-20T13:15:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283362749.md)
  - [en](https://longbridge.com/en/news/283362749.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283362749.md)
---

# Bicycle Therapeutics: Early EphA2-Targeted Data and Multi-Tumor Expansion Potential Support Buy Rating and Upside to Valuation

Bicycle Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami Fadia from Needham maintained a Buy rating on the stock and has a $15.00 price target.

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Ami Fadia has given his Buy rating due to a combination of factors tied to encouraging early clinical and preclinical data for Bicycle Therapeutics’ lead asset, nuzefatide pevedotin. In metastatic urothelial carcinoma, the drug’s combination with nivolumab produced a 100% response rate in EphA2‑positive, MMAE‑naïve patients and a 40% overall response rate in the EphA2‑positive subgroup, which compares favorably to prior, largely unsuccessful efforts to drug EphA2.

Beyond urothelial cancer, initial pancreatic cancer data showed rapid tumor localization with clearance mainly via the kidneys in most patients, and preclinical models indicated broad sensitivity, suggesting meaningful expansion potential. Similar supportive preclinical findings in head and neck squamous cell carcinoma further strengthen the multi‑tumor opportunity, and investors are also anticipating more detailed Phase 2 results for zelenectide pevedotin in first‑line mUC, which together underpin Fadia’s constructive view on BCYC’s valuation and growth prospects.

### Related Stocks

- [BCYC.US](https://longbridge.com/en/quote/BCYC.US.md)

## Related News & Research

- [Tango Therapeutics' pancreatic cancer drug combo shows promise in study](https://longbridge.com/en/news/289053428.md)
- [Why Tango Therapeutics (TNGX) Is Up 33.9% After Highlighting Pancreatic Cancer Pipeline Data Prospects](https://longbridge.com/en/news/289140698.md)
- [BUZZ-IDEAYA Biosciences falls on $300 mln stock sale plans](https://longbridge.com/en/news/289103497.md)
- [‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer](https://longbridge.com/en/news/288606083.md)
- [AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment For Ampligen In Pancreatic Cancer; Stock Down](https://longbridge.com/en/news/288598131.md)